Cytosine

Cytosine

SCHEMBL1687124

Nc1cc[nH]c(=O)n1.O=P(O)(O)OC1O[C@H](CO)[C@@H](O)[C@@H]1O

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
LMNA P02545 2/20 0.41
THRB P10828 1/20 0.41
MTOR P42345 1/20 0.41
MDM2 Q00987 1/20 0.41
NCOA1 Q15788 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
P2RY14 Q15391 5/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
POLB P06746 1/20 0.39
P2RY2 P41231 5/20 0.38
P2RY6 Q15077 5/20 0.38
ADORA1 P30542 1/20 0.38
P2RY4 P51582 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cytosine SCHEMBL9768402 0.92 P2RY14 (0.45) ALDH1A1P2RY14P2RY2P2RY6P2RY4
Cytosine SCHEMBL672261 0.90 P2RY6 (0.46) ALDH1A1P2RY14P2RY2P2RY6P2RY4
Ribose (Furanose) SCHEMBL3341287 0.82 LMNA (0.49) ALDH1A1LMNATHRBMTORMDM2
Ribose (Furanose) SCHEMBL8833 0.82 LMNA (0.49) ALDH1A1LMNATHRBMTORMDM2
Ribose (Furanose) SCHEMBL2325834 0.82 LMNA (0.49) ALDH1A1LMNATHRBMTORMDM2
Ribose (Furanose) SCHEMBL142622 0.82 LMNA (0.49) ALDH1A1LMNATHRBMTORMDM2
SCHEMBL5369246 0.81 P2RY14 (0.39) ALDH1A1P2RY14P2RY2P2RY6ADORA1
Ribose (Furanose) SCHEMBL628713 0.81 LMNA (0.48) ALDH1A1LMNATHRBMTORMDM2
Ribose (Furanose) SCHEMBL561196 0.81 LMNA (0.48) ALDH1A1LMNATHRBMTORMDM2
Cytosine SCHEMBL11321353 0.79 FBP1 (0.47) P2RY14P2RY2P2RY6P2RY4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230110614-A1 HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS ATOSSA THERAPEUTICS, INC. 2023-04-13 US claimed
EP-4125936-A1 HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS Atossa Therapeutics, Inc. (US) 2023-02-08 EP claimed
WO-2021194890-A1 HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS ATOSSA THERAPEUTICS, INC. (US) 2021-09-30 WO claimed
US-4701521-A BONDING TO CATIONIC POLYMER THE TRUSTEES OF BOSTON UNIVERSITY (US) 1987-10-20 US claimed
EP-0009498-B1 EFFECTING CELLULAR UPTAKE OF MOLECULES TRUSTEES OF BOSTON UNIVERSITY (US) 1984-06-27 EP claimed
EP-0009498-A4 EFFECTING CELLULAR UPTAKE OF MOLECULES. UNIV BOSTON (US) 1980-10-16 EP claimed
EP-0009498-A1 EFFECTING CELLULAR UPTAKE OF MOLECULES. UNIV BOSTON (US) 1980-04-16 EP claimed
WO-1979000515-A1 METHOD OF EFFECTING CELLULAR UPTAKE OF MOLECULES UNIV BOSTON (US) 1979-08-09 WO claimed
US-12576103-B2 Heparin and N-acetylcysteine for the treatment of lung injury ATOSSA THERAPEUTICS, INC. (US) 2026-03-17 US disclosed
WO-2024189607-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT DIDENKO KIRILL (MX) 2024-09-19 WO disclosed
US-20230278957-A1 TREX1 INHIBITORS AND USES THEREOF UNIV WAKE FOREST HEALTH SCIENCES (US) 2023-09-07 US disclosed
US-20230110614-A1 HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS ATOSSA THERAPEUTICS, INC. 2023-04-13 US disclosed
US-20230105879-A1 Antiviral Composition KLELE LUKE (US) 2023-04-06 US disclosed
EP-4135660-A1 COMPOSITIONS AND METHODS TO REDUCE THE INFECTIVITY OF A VIRUS Atossa Therapeutics, Inc. (US) 2023-02-22 EP disclosed
US-4847240-A CATIONIC POLYMERS AS TRANSPORT CARRIERS THE TRUSTEES OF BOSTON UNIVERSITY (US) 1989-07-11 US disclosed
US-4701521-A BONDING TO CATIONIC POLYMER THE TRUSTEES OF BOSTON UNIVERSITY (US) 1987-10-20 US disclosed
EP-0009498-B1 EFFECTING CELLULAR UPTAKE OF MOLECULES TRUSTEES OF BOSTON UNIVERSITY (US) 1984-06-27 EP disclosed
EP-0009498-A4 EFFECTING CELLULAR UPTAKE OF MOLECULES. UNIV BOSTON (US) 1980-10-16 EP disclosed
EP-0009498-A1 EFFECTING CELLULAR UPTAKE OF MOLECULES. UNIV BOSTON (US) 1980-04-16 EP disclosed
WO-1979000515-A1 METHOD OF EFFECTING CELLULAR UPTAKE OF MOLECULES UNIV BOSTON (US) 1979-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278957-A1 TREX1 INHIBITORS AND USES THEREOF STING1, CGAS, MAVS ALDH1A1 3221/4885LMNA 1096/4885THRB 1247/4885
US-20230105879-A1 Antiviral Composition MAVS, SARS1, ACE2 ALDH1A1 1990/4885LMNA 1965/4885THRB 2647/4885
US-12576103-B2 Heparin and N-acetylcysteine for the treatment of lung injury SERPINC1, TXNRD2, TXN ALDH1A1 3305/4885LMNA 2782/4885THRB 1561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.